Revenue Performance - Total revenue for Q3 2024 was $80.5 million, compared to $56.1 million in Q3 2023, representing a 43.5% increase[8]. - Total revenue for Q3 2024 was $80.5 million, a 43.4% increase from $56.1 million in Q3 2023[27]. - Product revenue, net for Q3 2024 was $56.1 million, a 8.7% increase from $51.6 million in Q3 2023[3]. - Product revenue for Q3 2024 reached $56.1 million, up from $51.6 million in Q3 2023, representing a 8.7% growth[27]. - Royalty revenue surged to $24.4 million in Q3 2024, compared to $4.5 million in Q3 2023, marking a significant increase of 442.2%[27]. Net Income and Earnings - Net income for Q3 2024 was $20.3 million, or $0.41 per share, compared to $5.8 million, or $0.12 per share in Q3 2023, marking a 249.1% increase in net income[4]. - Net income for Q3 2024 was $20.3 million, a substantial rise from $5.8 million in Q3 2023, reflecting a 249.1% increase[27]. - Basic net income per share for Q3 2024 was $0.41, compared to $0.12 in Q3 2023, indicating a 241.7% increase[27]. - Non-GAAP adjusted net income for Q3 2024 was $22.4 million, or $0.46 per share, compared to $8.3 million, or $0.18 per share in Q3 2023, reflecting a 170.1% increase[5]. - Non-GAAP adjusted net income for Q3 2024 was $22.4 million, significantly higher than $8.3 million in Q3 2023[29]. Operating Costs and Expenses - Operating costs and expenses for Q3 2024 were $58.4 million, up from $47.5 million in Q3 2023, indicating an increase of 22.8%[9]. - Research and development expenses for Q3 2024 were $12.5 million, compared to $11.4 million in Q3 2023, a year-over-year increase of 9.6%[12]. - Total other expenses for Q3 2024 were $1.5 million, down from $2.6 million in Q3 2023, reflecting a decrease of 42.3%[13]. Cash and Financial Position - Cash, cash equivalents, and marketable securities as of September 30, 2024, were approximately $97 million, slightly up from $96 million at the end of 2023[6]. - Cash and cash equivalents as of September 30, 2024, were $67.3 million, down from $84.6 million at the end of 2023[28]. - Long-term debt decreased to $32.7 million as of September 30, 2024, from $65.7 million at the end of 2023[28]. - Stockholders' equity increased to $71.1 million as of September 30, 2024, compared to $53.4 million at the end of 2023[28]. - Cash provided by operating activities for the nine months ended September 30, 2024, was $23.3 million, compared to $16.6 million for the same period in 2023[28]. Future Guidance and Development - The company anticipates Q4 2024 net product revenue between $46 million and $48 million, and full-year 2024 net income guidance revised to $15 million to $17 million[14]. - The company is progressing with clinical development of alisertib, with key milestones expected in the next 12 months, including the initiation of a Phase II trial in Q4 2024[7].

PHILADELPHIA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Puma Biotechnology, Inc. ("Puma") (NASDAQ: PBYI) on behalf of the company's shareholders. Click for additional information: https://kaskelalaw.com/case/puma-biotechnology/ Since February 2024, shares of Puma's stock have declined in value from a trading price of over $7.25 per share to a current trading price of less than $3.00 per share, a decline of over $4.25 per share, or over 58% in value. The investigati ...

Puma Biotechnology, Inc. (PBYI) reported second-quarter 2024 adjusted loss of 5 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago quarter, the company had reported adjusted earnings of 10 cents. The above-adjusted loss excludes the impact of stock-based compensation expense. Including the same, the reported loss per share was 9 cents in the second quarter of 2024 against earnings of 5 cents reported in the year-ago quarter. In the second quarter, to ...

Puma Biotechnology Earnings Call Commercial Update August 1, 2024 Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These sta ...

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2024 Earnings Call August 1, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chief Executive Officer, President and Chairman Maximo Nougues - Chief Financial Officer Jeff Ludwig - Chief Commercial Officer Conference Call Participants Marc Frahm - TD Cowen Ed White - H.C. Wainwright Operator Good afternoon. My name is Diego and I will be your conference call operator today. [Operator Instructions] As a remi ...

Puma Biotech (PBYI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 50%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.16 per share when it actually produced a loss of $0.05, delivering a surprise of 68.75%. Over the last four quarters, the com ...

Financial Performance - Total revenue for Q2 2024 was $47.083 million, a decrease of 13.8% compared to $54.568 million in Q2 2023[9] - Product revenue, net for Q2 2024 was $44.395 million, down from $51.551 million in Q2 2023, representing a decline of 13.3%[9] - Net loss for Q2 2024 was $4.529 million, compared to a net income of $2.126 million in Q2 2023, indicating a significant shift in financial performance[10] - Comprehensive loss for Q2 2024 was $4.535 million, compared to a comprehensive income of $2.120 million in Q2 2023[10] - The company reported a net loss of approximately $9.3 million for the six months ended June 30, 2024, compared to a net income of $3.5 million for the same period in 2023[23] - Total revenue for the six months ended June 30, 2024, was approximately $90.8 million, down from $107.3 million for the same period in 2023, primarily due to a $13.7 million decrease in product revenue[171] - Product revenue, net decreased by approximately 16.1% to $84.7 million for the six months ended June 30, 2024, compared to $98.3 million for the same period in 2023[172] Operating Costs and Expenses - Operating costs and expenses totaled $49.262 million in Q2 2024, slightly down from $49.676 million in Q2 2023[9] - Total operating costs and expenses for the first half of 2024 were $95.327 million, down from $98.086 million in the same period of 2023[9] - SG&A expenses increased by approximately $0.5 million to $25.0 million for the three months ended June 30, 2024, compared to $24.5 million for the same period in 2023, primarily due to a $2.7 million increase in professional fees[165] - SG&A expenses for the six months ended June 30, 2024, were approximately $46.7 million, a slight decrease from $46.9 million for the same period in 2023[174] Research and Development - Research and development expenses were $13.632 million in Q2 2024, compared to $13.357 million in Q2 2023, reflecting a 2% increase[9] - R&D expenses rose by approximately $0.3 million to $13.6 million for the three months ended June 30, 2024, compared to $13.4 million for the same period in 2023, mainly driven by a $0.5 million increase in internal R&D[166] - R&D expenses for the six months ended June 30, 2024, were approximately $27.2 million, up from $26.1 million for the same period in 2023, driven by a $0.9 million increase in clinical trial expenses[176] Cash and Liquidity - Cash provided by operating activities was approximately $12.3 million for the six months ended June 30, 2024, up from $5.9 million in the prior year[23] - The company had cash, cash equivalents, and marketable securities totaling approximately $96.8 million as of June 30, 2024[23] - Cash and cash equivalents as of June 30, 2024, were approximately $67.1 million, down from $84.6 million as of December 31, 2023[179] - The company has approximately $67.1 million in cash and cash equivalents and $29.7 million in marketable securities available as of June 30, 2024[191] Debt and Financing - Long-term debt as of June 30, 2024, totals $102,000,000, with a net amount of $43,735,000 after accounting for issuance costs and current portion[108] - The effective interest rate for the Athyrium Notes as of June 30, 2024, is 12.99%, with quarterly principal payments approximating $11.1 million[112] - The principal balance outstanding under the Athyrium Notes as of June 30, 2024 was $88.9 million, representing all of the company's debt[190] - The company is in compliance with all applicable covenants under the Athyrium Notes[190] Product Development and Commercialization - The company has entered into an exclusive license agreement with Takeda for the worldwide research and development rights to alisertib[22] - The company is commercializing NERLYNX® for HER2-positive breast cancer and has plans for further commercialization in various regions outside the United States[22] - NERLYNX is currently approved in over 40 countries outside the United States for treating certain patients with HER2-positive breast cancer[152] - The company plans to initiate the ALISCA™ -Breast1 trial in the second half of 2024, following the ALISCA™ -Lung1 trial commenced in February 2024[153] Legal Matters - The jury awarded Wyeth $107,500,000 for past acts of infringement through December 31, 2023, in the AstraZeneca litigation[136] - The Company filed a civil lawsuit against Acebright for infringement of the '789 patent, seeking to enjoin Acebright's offer for sale of a generic version of NERLYNX®[139] - The NMPA approved Acebright's ANDA to market a generic version of NERLYNX® in China on September 12, 2023[138] - The Company has filed four Article 76 petitions against Convalife's ANDA with CNIPA, which were accepted on February 3, 2023[144] Inventory and Accounts Receivable - As of June 30, 2024, total inventories increased to $9,049,000 from $7,080,000 as of December 31, 2023, representing a 27.8% increase[83] - The company's accounts receivable, net decreased to $28,105,000 as of June 30, 2024, down from $47,837,000 as of December 31, 2023, a decline of 41.2%[96] Stock and Compensation - The company issued 813,333 shares of common stock upon vesting of RSUs during the six months ended June 30, 2024[118] - Total stock-based compensation expense for the three months ended June 30, 2024 was $2,062,000, compared to $2,432,000 for the same period in 2023[123] - The total estimated unrecognized employee compensation cost related to non-vested stock options was approximately $1.8 million, expected to be recognized over a weighted-average period of 1.3 years[124]

News Release Exhibit 99.1 Puma Biotechnology Reports Second Quarter Financial Results LOS ANGELES, Calif., Aug. 1, 2024 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2024. Unless otherwise stated, all comparisons are for the second quarter 2024 compared to the second quarter 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the sec ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Puma Biotechnology (PBYI) is a stock many investors are watching right now. PBYI is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. Finally, investors will want to recognize that PBYI has a P/CF ratio of 6.55. This met ...

Shares of Puma Biotechnology, Inc. (PBYI) have plunged 38.4% in the past three months compared with the industry's decline of 4.8%. The company's sole marketed product, Nerlynx (neratinib), is approved for the treatment of early-stage HER2- positive breast cancer in patients who have been previously treated with Roche's (RHHBY) Herceptin-based adjuvant therapy. Demand for Nerlynx has been declining in recent quarters. Owing to this, sales of the drug have been falling over the past couple of quarters. Being ...